Metachronous mature teratoma in the corpus callosum occurring 12 years after a pineal germinoma

2008 ◽  
Vol 109 (1) ◽  
pp. 126-129 ◽  
Author(s):  
Yuuta Kamoshima ◽  
Yutaka Sawamura ◽  
Motoyuki Iwasaki ◽  
Yoshinobu Iwasaki ◽  
Kazuhiko Sugiyama
Keyword(s):  
Corpus Callosum ◽  
Mr Imaging ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Tumor Size ◽  
Mature Teratoma ◽  
Cell Tumor ◽  
Pineal Germinoma ◽  
Second Tumor

The authors report a metachronous germ cell tumor with different histological type occurring 12 years after resection of a pineal germinoma. Histological examination of the original tumor revealed germinoma without any other component of germ cell tumor, and the patient underwent chemotherapy followed by 24 Gy of localized irradiation. Twelve years later, follow-up MR imaging showed a round mass in the genu of the corpus callosum. Two courses of chemotherapy were administered, but the tumor size remained stable. A second operation was performed and this second tumor was completely removed. The histological diagnosis was mature teratoma. The second tumor was considered as a metachronous mature teratoma rather than a recurrence of the original germinoma. To the authors' knowledge, this combination of metachronous germ cell tumor has not previously been reported in the literature

scholarly journals Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups.

1995 ◽  
Vol 13 (5) ◽  
pp. 1177-1187 ◽  
Author(s):  
E W Steyerberg ◽  
H J Keizer ◽  
S D Fosså ◽  
D T Sleijfer ◽  
G C Toner ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Individual Patient Data ◽  
Mature Teratoma ◽  
Study Groups ◽  
Patient Data ◽  
Cell Tumor ◽  
Data Set ◽  
Nonseminomatous Germ Cell Tumor

PURPOSE To develop a statistical model that predicts the histology (necrosis, mature teratoma, or cancer) after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT). PATIENTS AND METHODS An international data set was collected comprising individual patient data from six study groups. Logistic regression analysis was used to estimate the probability of necrosis and the ratio of cancer and mature teratoma. RESULTS Of 556 patients, 250 (45%) had necrosis at resection, 236 (42%) had mature teratoma, and 70 (13%) had cancer. Predictors of necrosis were the absence of teratoma elements in the primary tumor, prechemotherapy normal alfa-fetoprotein (AFP), normal human chorionic gonadotropin (HCG), and elevated lactate dehydrogenase (LDH) levels, a small prechemotherapy or postchemotherapy mass, and a large shrinkage of the mass during chemotherapy. Multivariate combination of predictors yielded reliable models (goodness-of-fit tests, P > .20), which discriminated necrosis well from other histologies (area under the receiver operating characteristic (ROC) curve, .84), but which discriminated cancer only reasonably from mature teratoma (area, .66). Internal and external validation confirmed these findings. CONCLUSION The validated models estimate with high accuracy the histology at resection, especially necrosis, based on well-known and readily available predictors. The predicted probabilities may help to choose between immediate resection of a residual mass or follow-up, taking into account the expected benefits and risks of resection, feasibility of frequent follow-up, the financial costs, and the patient's individual preferences.

scholarly journals Clinical Characteristics of Testicular Nonseminomatous Germ Cell Tumor from West China: A 10-Year Experience of a Super regional Center

2019 ◽  
Author(s):  
Zeyu Chen ◽  
Xingyuan Wang ◽  
Dehong Cao ◽  
Shi Qiu ◽  
Jianbing Guo ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Tumor Size ◽  
Clinical Characteristics ◽  
Clinical Stage ◽  
Cell Tumor ◽  
Stage Iii ◽  
West China ◽  
Nonseminomatous Germ Cell Tumor

Abstract Obejectives: To evaluate the clinical characteristics and prognostic factors of Nonseminomatous Germ Cell Tumor (NSGCT). Patients and methods: Testicular cancer (TC) survey was conducted by Department of Urology, West China Hospital from 2008 to 2018. Details such as age, tumor size, tumor markers, histopathology, clinical stage, initial treatment, follow up, and clinical outcomes were provided by the database of our center. Tumor stage was classified according to the NCCN criteria(1). Results: Orchiectomy, chemotherapy and radio-therapy were the main treatments for these patients. Clinical stage I, stage II and stage III patients accounted for 74.6% (150), 7.5% (15) and 17.9% (36), respectively. After a median follow up time of 63 months, 4 patients relapsed during observation and 3 of them died. 4 patients died because of advanced malignancies. Among CSI patients, 2 relapsed and 1 died in 3 months after orchiectomy. No recurrence was found in CSII patients. 2 out of 29 stage III cases relapsed after treatment and 3 died of advanced cancer. The 3- and 10- year OS was 95.6% and 88.7%, respectively. For all the patients, the 3- and 10-year PFS was 94.9% and 88.8%. According to our data, we found that the meatastasis and tumor size were risk factors for NSGCTs. Conclusion: The present report showed a good prognosis at non-metastatic stage(CSI). However, the prognosis of advanced disease(CSII and CSIII) is significantly worse than that of early stage. We also found that maximum tumor diameter of >5cm was a potential risk factor for NSGCT.

Cytogenetic analysis of the mature teratoma and the choriocarcinoma component of a testicular mixed nonseminomatous germ cell tumor

1992 ◽  
Vol 61 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Willem E. de Graaff ◽  
J. Wolter Oosterhuis ◽  
Bauke de Jong ◽  
Jannie van Echten-Arends ◽  
Janneke Wiersema-Buist ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Cytogenetic Analysis ◽  
Mature Teratoma ◽  
Cell Tumor ◽  
Nonseminomatous Germ Cell Tumor

scholarly journals MPC-08 CLINICOPATHOLOGICAL ANALYSIS OF 12P GAIN IN INTRACRANIAL GERM CELL TUMORS

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii23-ii23
Author(s):  
Kaishi Satomi ◽  
Hirokazu Takami ◽  
Shintaro Fukushima ◽  
Yoichi Nakazato ◽  
Shota Tanaka ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Copy Number ◽  
Mature Teratoma ◽  
Methylation Status ◽  
Germ Cell Tumors ◽  
Copy Number Variations ◽  
Cell Tumor ◽  
Testicular Germ Cell ◽  
Intracranial Germ Cell Tumor

Abstract BACKGROUND Gain of short arm of chromosome 12 (12p) is commonly observed in testicular germ cell tumors (tGCTs). 12p gain is also frequently seen in intracranial GCTs (iGCTs). However, little is known about the clinical significance of 12p gain in iGCTs. MATERIALS AND METHODS We have collected over 200 fresh frozen tissue samples of iGCTs through the Intracranial Germ Cell Tumor Genome Analysis Consortium in Japan. Firstly, we analyzed DNA methylation status in 83 iGCTs, 3 seminomas and 6 normal control samples using Infinium Human Methylation 450K BeadChip array (Illumina, CA). Idat files were processed using R (Version 3.5.3) and minfi package (1.30.0) to generate copy number variations. Compared with average genome-wide copy number level, 12p gain was determined. Then, 58 iGCTs with clinicopathological information were analyzed for progression-free survival (PFS) and overall survival (OS). Those tumors that consist of only either germinoma and/or mature teratoma components were classified as Favorable Histology (FH) and all the others that contains malignant histological components were classified as Unfavorable Histology (UFH). RESULT 12p gain was observed in 100% (3/3) of seminoma, 13.6% (3/22) of germinoma, 16.7% (1/6) of mature teratoma, 25% (1/4) of immature teratoma, 55% (11/20) of mixed germ cell tumor, 100% (4/4) of yolk sac tumor, 100% (1/1) of embryonal carcinoma, and 100% (1/1) of choriocarcinoma. In total, 44.6% (37/83) of iGCT showed 12p gain. Regarding histological classification, the 12p gain rate in UFH (72%, 18/25) was significantly higher than that in FH (12.1%, 4/33, P<0.01). Both PFS and OS were significantly worse in iGCTs with 12p gain (PFS: P=0.027, OS: P=0.0012). DISCUSSION 12p gain can be a molecular marker to predict prognosis and histological malignancy in iGCTs.

Prediction of a potential lethal phenotype in testicular nonseminomatous germ cell tumor.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15575-e15575
Author(s):  
Mehmet Asim Bilen ◽  
Sue-Hwa Lin ◽  
Rosale General ◽  
Lance C. Pagliaro ◽  
Christopher Logothetis ◽  
...  
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Tumor Size ◽  
Primary Tumor ◽  
Embryonal Carcinoma ◽  
Univariate Analysis ◽  
Prognostic Significance ◽  
Cell Tumor ◽  
Lethal Phenotype ◽  
Nonseminomatous Germ Cell Tumor

e15575 Background: Cancer is a heterogeneous disease. The nature of heterogeneity provides clues about the biologic origin of cancer. Studying cancer heterogeneity may enable us to elucidate the various subtypes of a particular cancer, and improve the diagnosis, prognostication, and therapy of cancer. Nonseminomatous germ cell tumor (NSGCT) is a prime example of a heterogeneous disease. We determined the lethality of NSGCT by characterizing the histological makeup of primary testicular tumors (proportion of embryonal carcinoma [EC], choriocarcinoma, seminoma, yolk sac tumor [YST], and teratoma) and their tumor burden. Methods: From November 1997 to October 2012, 142 consecutive patients diagnosed with a NSGCT were included for this study. Predictors significant in univariate analysis: tumor stage, tumor size, percentage of YST component, and percentage of EC component were used as predictors of cancer specific death or incurability in a multivariate binary logistic regression model. The outcome of the model is probability of death or incurability. Results: Patient characteristics: age, median (range) – 25 (12-53); race – Caucasians 65%, Hispanics 28%; pathology – embryonal carcinoma 15%, teratoma 6%, mixed NSGCT 79%; stage – I 43%, II 33%, III 24%; size of primary tumor, median (range) – 3.8 cm (0.9-27); HCG<5,000 95%, >5,000 4%; AFP<1,000 85%, >1,000 13%; therapy – salvage chemotherapy 15%, RPLND 34%, HD chemotherapy w/ SCT 1%, WBRT 1%. Univariate analysis showed that clinical stage (p=.0001), presence of YST (p<.005), size of primary tumor (p=.005), and absence of EC (<.01) have prognostic significance. We developed a nomogram to identify patients who are most likely to succumb to their NSGCT based on the histologic makeup of their primary tumor, size of the primary tumor, initial tumor markers, and appropriate surgeries after chemotherapy. Conclusions: Presence of YST in advanced NSGCT predicts chemotherapy resistance in a potentially lethal phenotype. Early diagnosis and timely treatment with chemotherapy and surgery may improve the clinical outcome of these patients. Results of this study need to be validated in another data base or a prospective clinical trial.

Testicular Mixed Germ Cell Tumor with Polyembryoma Component in Brothers

2005 ◽  
Vol 8 (1) ◽  
pp. 92-97 ◽  
Author(s):  
Sevgi Bakaris ◽  
Sefa Resim ◽  
Nurdan Tunali
Keyword(s):  
Germ Cell ◽  
Germ Cell Tumor ◽  
Embryonal Carcinoma ◽  
Mature Teratoma ◽  
Testicular Tumor ◽  
Serum Levels ◽  
High Serum ◽  
Cell Tumor ◽  
Mixed Germ Cell Tumor ◽  
The Right

We report the case of a 17-year-old male with a testicular tumor and high serum levels of α-fetoprotein. The patient was treated with surgery followed by combination chemotherapy with bleomycin, etoposide, and cisplatin. Histologic examination showed features of a mixed germ cell tumor composed of mature teratoma, immature teratoma, embryonal carcinoma, yolk sac tumor, and polyembryoma. He is currently well, and his serum levels of α-fetoprotein have been normal more than 5 months after treatment. His brother, aged 17 years at the time, had a similar tumor removed from the right testicle 5 years previously.

scholarly journals Ovarian Germ Cell Tumor with Myasthenia Gravis: Co-incidence or a Possible link?

2021 ◽  
Vol 6 (4) ◽  
pp. 525-527
Author(s):  
Jhanzeb Iftikhar ◽  
Fareeha Sheikh ◽  
Nazish Khalid ◽  
Muhammad Abubakar Sarwar ◽  
Musa Azhar ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Germ Cell ◽  
Germ Cell Tumor ◽  
Mature Teratoma ◽  
Surgical Excision ◽  
Cell Tumor ◽  
Ovarian Teratoma ◽  
First Case ◽  
Complete Surgical Excision ◽  
Ovarian Teratomas

Teratomas are a common form of germ cell tumor. Teratomas are commonly found in the gonadal organs, such as the ovaries and testes. Treatment of choice for ovarian teratomas is complete surgical excision, which exhibits a good prognosis in benign teratomas; however, chemotherapy treatment is needed for malignant components. Neurological paraneoplastic presentation of gynecological tumors is rare; however, ovarian tumors account for 10% of this presentation. In literature, paraneoplastic limbic encephalitis, anti-N-methyl-D-aspartate receptor encephalitis, and paraneoplastic cerebellar degeneration have been reported in ovarian teratomas and tumors; however, myasthenia gravis has been reported only twice. In both of those cases, manifestation of myasthenia gravis was preceding the diagnosis of ovarian cancer. We describe the first case of a 21-year-old female who presented with new-onset myasthenia gravis after finishing chemotherapy for ovarian teratoma. Another unusual aspect of our case is the rare co-occurrence of gliomatosis peritonei with mature teratoma.

Sign in / Sign up

Export Citation Format

Share Document